Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IV Safety Study of RIXUBIS in Hemophilia B Patients in India
2022-002520-13Phase 4
- Sponsor
- Baxalta
- Start
- Jul 2022
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of trenonacog alfa in hemophilia B (HB), sponsored by Baxalta. Primary endpoint: Incidence of SAEs (including FIX inhibitors) possibly or probably related to RIXUBIS.
02
Drugs
trenonacog alfa
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on 2022-002520-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002520-13.